EP1514106A4 - Gezielte therapeutische proteine - Google Patents

Gezielte therapeutische proteine

Info

Publication number
EP1514106A4
EP1514106A4 EP03736779A EP03736779A EP1514106A4 EP 1514106 A4 EP1514106 A4 EP 1514106A4 EP 03736779 A EP03736779 A EP 03736779A EP 03736779 A EP03736779 A EP 03736779A EP 1514106 A4 EP1514106 A4 EP 1514106A4
Authority
EP
European Patent Office
Prior art keywords
therapeutic proteins
targeted therapeutic
targeted
proteins
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03736779A
Other languages
English (en)
French (fr)
Other versions
EP1514106A1 (de
Inventor
Jonathan H Lebowitz
Stephen M Beverley
William S Sly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Original Assignee
Zystor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/272,531 external-priority patent/US20040005309A1/en
Application filed by Zystor Therapeutics Inc filed Critical Zystor Therapeutics Inc
Publication of EP1514106A1 publication Critical patent/EP1514106A1/de
Publication of EP1514106A4 publication Critical patent/EP1514106A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
EP03736779A 2002-05-29 2003-05-29 Gezielte therapeutische proteine Withdrawn EP1514106A4 (de)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US272531 1994-07-11
US38445202P 2002-05-29 2002-05-29
US384452P 2002-05-29
US38601902P 2002-06-05 2002-06-05
US386019P 2002-06-05
US40881602P 2002-09-06 2002-09-06
US408816P 2002-09-06
US10/272,531 US20040005309A1 (en) 2002-05-29 2002-10-16 Targeted therapeutic proteins
US44573403P 2003-02-06 2003-02-06
US445734P 2003-02-06
PCT/US2003/017211 WO2003102583A1 (en) 2002-05-29 2003-05-29 Targeted therapeutic proteins

Publications (2)

Publication Number Publication Date
EP1514106A1 EP1514106A1 (de) 2005-03-16
EP1514106A4 true EP1514106A4 (de) 2007-05-09

Family

ID=29716364

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03736779A Withdrawn EP1514106A4 (de) 2002-05-29 2003-05-29 Gezielte therapeutische proteine

Country Status (4)

Country Link
EP (1) EP1514106A4 (de)
AU (1) AU2003237314B2 (de)
CA (1) CA2487815A1 (de)
WO (1) WO2003102583A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4641705B2 (ja) 2001-04-30 2011-03-02 ザイストール セラピューティクス， インコーポレイテッド 治療的タンパク質の亜細胞標的化
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
WO2003032727A1 (en) * 2001-10-16 2003-04-24 Symbiontics Inc. Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
ES2368941T3 (es) 2003-01-06 2011-11-23 Angiochem Inc. Angiopep-1, compuestos relacionados y utilizaciones correspondientes.
JP4914224B2 (ja) * 2004-02-10 2012-04-11 バイオマリン ファーマシューティカル インコーポレイテッド 酸性αグルコシダーゼおよびそのフラグメント
EP1818395A1 (de) 2006-02-08 2007-08-15 Diatos Zusammensetzungen und Verfahren zur Behandlung der Lysosomen-Speichererkrankungen
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
WO2009018122A2 (en) 2007-07-27 2009-02-05 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the cns
EP3778652A1 (de) 2008-05-07 2021-02-17 BioMarin Pharmaceutical Inc. Auf lysosomen gerichtete peptide und verwendungen davon
RU2011118056A (ru) 2008-10-15 2012-11-27 Ангиокем Инк. Конъюгаты агонистов glp-1 и их применение
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
MX2011006685A (es) 2008-12-17 2011-09-27 Angiochem Inc Inhibidores de metaloproteinas de matriz de membrana tipo-1 y sus usos.
CN102510759A (zh) 2009-04-20 2012-06-20 安吉奥开米公司 利用与血管肽-2类似物结合的抗癌剂治疗卵巢癌
EP3075386B1 (de) 2009-06-17 2019-10-16 BioMarin Pharmaceutical Inc. Formulierungen für lysosomale enzyme
JP5932642B2 (ja) 2009-07-02 2016-06-08 アンジオケム インコーポレーテッド 多量体ペプチドコンジュゲートおよびその使用
DK2585104T3 (da) 2010-06-25 2019-10-14 Shire Human Genetic Therapies Fremgangsmåder og sammensætninger tilcns-levering af arylsulfatase a
AU2011270667B2 (en) 2010-06-25 2017-01-05 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of heparan N-sulfatase
EP3875107A1 (de) 2010-06-25 2021-09-08 Shire Human Genetic Therapies, Inc. Pharmazeutische formulierung enthaltend ein ersatzenzym für das lysosomale enzym zur intrathecalen behandlung der lysosomalen speicherkrankheit
US8545837B2 (en) 2010-06-25 2013-10-01 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of iduronate-2-sulfatase
SI3626258T1 (sl) 2010-06-25 2021-11-30 Shire Human Genetic Therapies, Inc. Postopki in sestavki za dovajanje idunorat-2-sulfataze v cžs
JP6063380B2 (ja) 2010-06-25 2017-01-18 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド サンフィリポ症候群ｂ型の処置
AU2012344702A1 (en) * 2011-12-01 2014-06-19 Angiochem Inc. Targeted lysosomal enzyme compounds
CA2857548A1 (en) * 2011-12-01 2013-06-06 Angiochem Inc. Targeted enzyme compounds and uses thereof
US20140377244A1 (en) 2011-12-23 2014-12-25 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
BR112014031273A2 (pt) * 2012-06-15 2017-07-25 Angiochem Inc compostos enzima alvejados e seus usos
HUE039334T2 (hu) 2012-11-27 2018-12-28 Biomarin Pharm Inc Célzott terápiás lizoszómális enzim fúziós fehérjék és azok alkalmazásai
CA2892763A1 (en) * 2012-11-30 2014-06-05 Angiochem Inc. Targeted iduronate-2-sulfatase compounds
ES2759503T3 (es) 2013-05-02 2020-05-11 Glykos Finland Oy Conjugados de una glicoproteína o un glicano con una carga útil tóxica
WO2014194428A1 (en) * 2013-06-06 2014-12-11 Angiochem Inc. Targeted heparan sulfatase compounds
EP3160513B1 (de) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharidderivat einer toxischen nutzlast und antikörperkonjugate davon
US10556015B2 (en) 2014-10-24 2020-02-11 Criteo S.A. Lysosomal targeting of enzymes, and uses thereof
JP6823055B2 (ja) 2015-06-15 2021-01-27 アンジオケム インコーポレーテッド 軟髄膜癌腫症の治療方法
US11345904B2 (en) 2016-02-24 2022-05-31 Biomarin Pharmaceutical Inc. Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof
WO2020132452A1 (en) 2018-12-20 2020-06-25 Shire Human Genetic Therapies, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087510A2 (en) * 2001-04-30 2002-11-07 Symbiontics, Inc. Subcellular targeting of therapeutic proteins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032727A1 (en) * 2001-10-16 2003-04-24 Symbiontics Inc. Methods and compositions for targeting underglycosylated proteins across the blood brain barrier

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087510A2 (en) * 2001-04-30 2002-11-07 Symbiontics, Inc. Subcellular targeting of therapeutic proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NOLAN C M ET AL: "BINDING OF INSULIN-LIKE GROWTH FACTOR II (IGF-II) BY HUMAN CATION-INDEPENDENT MANNOSE 6-PHOSPHATE RECEPTOR/IGF-II RECEPTOR EXPRESSED IN RECEPTOR-DEFICIENT MOUSE L CELLS", CELL REGULATION, BETHESDA,MD, US, vol. 1, no. 2, January 1990 (1990-01-01), pages 197 - 213, XP008053772, ISSN: 1044-2030 *
See also references of WO03102583A1 *

Also Published As

Publication number Publication date
CA2487815A1 (en) 2003-12-11
WO2003102583A1 (en) 2003-12-11
AU2003237314A1 (en) 2003-12-19
EP1514106A1 (de) 2005-03-16
AU2003237314B2 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
EP1514106A4 (de) Gezielte therapeutische proteine
GB0206876D0 (en) Therapeutic agents
GB0229931D0 (en) Therapeutic agents
GB0209991D0 (en) Therapeutic agents
GB0209995D0 (en) Therapeutic agents
GB0209997D0 (en) Therapeutic agents
GB0210127D0 (en) Therapeutic agents
GB0230087D0 (en) Therapeutic agents
GB0210124D0 (en) Therapeutic agents
GB0223349D0 (en) Therapeutic agents
GB0230088D0 (en) Therapeutic agents
GB0218876D0 (en) Therapeutic agents
GB0219660D0 (en) Therapeutic use
AU2003226899A8 (en) Human diabetes-mediating proteins
GB0217068D0 (en) Therapeutic agents
GB0226462D0 (en) Therapeutic agents
GB0225501D0 (en) Therapeutic agents
GB0208394D0 (en) Therapeutic agents
GB0201808D0 (en) Protein
AU2003278718A8 (en) Stars-a muscle-specification-binding protein
AU2003231937A8 (en) Therapeutic methods
GB0213383D0 (en) Therapeutic conditions
GB0225399D0 (en) Therapeutic agents
GB0215406D0 (en) Protein
GB0217069D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1076863

Country of ref document: HK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BEVERLEY, STEPHEN, M.

Inventor name: SLY, WILLIAM, S.

Inventor name: LEBOWITZ, JONATHAN, H.

A4 Supplementary search report drawn up and despatched

Effective date: 20070405

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOMARIN PHARMACEUTICAL INC.

17Q First examination report despatched

Effective date: 20121031

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130312

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1076863

Country of ref document: HK